This study aimed to explore the anti-tumor activity and mechanisms of action of isorhamnetin, a compound isolated from Astragalus membranaceus, in combination with sorafenib for treatment of renal cell carcinoma (RCC). The anti-tumor activity of isorhamnetin in combination with sorafenib was detected by MTT assay with cells in culture or Renca xenograft model in mice. Western blot was used to study the mechanisms of isorhamnetin in combination with sorafenib. Lymphocyte proliferation assay was also used to investigate the effects of the two drugs in combination. The results indicated that isorhamnetin inhibited the proliferation of RCC cells, with IC₅₀ for A498, 786-O and Renca cell lines with being 31.7, 28.8 and 106.0 μmol·L^-1, respectively. Isorhamnetin in combination with sorafenib improved the anti-lymphocyte proliferation activity of sorafenib with the IC₅₀ down to 12.0 μmol·L^-1. Isorhamnetin inhibited the growth of RCC in mice slightly with the inhibition efficiency at 26.9%. With 50.0 mg·kg^-1 isorhamnetin in combination with 20.0 mg·kg^-1 sorafenib, the anti-tumor activity of sorafenib was enhanced, with inhibition of growth rate increased to 60.7%. Meanwhile, isorhamnetin in combination with sorafenib could promote the lymphocytes proliferation in Renca xenograft model. Western blot results showed that combination of isorhamnetin and sorafenib could inhibit c-Raf/MEK/ERK and AKT/mTOR signaling pathways. In conclusion, the combination of isorhamnetin with sorafenib could increase the anti-tumor activity of sorafenib in RCC in vitro and in vivo. The mechanisms may be related to the inhibition of c-Raf/MEK/ERK and AKT/mTOR signaling pathways. Procedures for animal study were performed with approval of the Animal Care and Use Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College.

We studied the effect of aqueous extract from Huang qi on gene expression profile of doxorubicin induced nephropathy in rats, and explored the molecular mechanism of the intervention. The gene expression profiles of control group, model group and aqueous extract from Huang qi group were detected by using transcriptome sequencing technique. The differentially expressed genes (DEGs) were screened by STEM trend analysis software. GO function enrichment and KEGG pathway analysis were performed for DEGs, and the gene expression level was verified by real-time fluorescence quantitative PCR (RT-qPCR). The results showed that, compared with the control group, 432 DEGs were obtained in doxorubicin nephropathy model group; compared with the model group, 811 DEGs were obtained due to aqueous extract of Huang qi. The results of GO function enrichment and KEGG enrichment analysis indicated that PI3K-AKT pathway (Col6a6, Nr4a1, Sgk1, Gng7) and lipid metabolism-related genes (Cpt1b, Pcsk9, Abca1, Ascm5) were the key pathways and genes in the treatment of doxorubicin induced nephropathy by aqueous extract from Huang qi, which played a protective role in kidney. In conclusion, the molecular mechanism of aqueous extract from Huang qi in protection against doxorubicin induced nephropathy rats is closely related to apoptosis-related genes and lipid metabolism-related genes, suggesting for the need of follow-up study for key gene validation and mechanism of action of aqueous extract from Huang qi for prevention of doxorubicin induced nephropathy.

Based on dehydrogenation of monocrotaline-induced Beagle dog model of pulmonary hypertension (PH), GC-TOF-MS metabolomics technique was used to identify potential biomarkers and biologically significant changes in the serum. Pattern recognition method was used for processing metabolomics data to compare PH Beagle dogs (n=11) versus healthy controls (n=8). The results show that 514 compounds were detected in the serum. The profiles of PH models and healthy controls can be distinguished clearly, indicating that there are significant differences in the metabolic profiles. Data analysis revealed 15 types of potential biomarkers, including amino acids glycine and 3-cyanoalanine, glucose, fructose, 1-monopalmitic acid glycerin, and malic acid. Diversified metabolites and their metabolic pathways have been analyzed. We found that different degrees of turbulence and disorganization occurred in glyoxylate and dicarboxylate metabolism, TCA cycle, starch and sucrose metabolism pathways in the Beagle dogs. A soluble guanylate cyclase activator, 4, 6-diamino-2-[1-(3-fluorothiophen-2-yl) methyl-1H-pyrazolo[3, 4-b]pyridin-3-yl] -5-pyrimidinyl-N-methyl methyl carbamate (sGC003), was administered (n=15) for comparison with the model and the control. We found that three groups were clearly clustered, indicating that there were differences in the three groups of metabolites. ANOVA statistical analysis results suggested that sGC003 exhibited pharmacodynamic effect, and at the same time, it also changed the endogenous metabolites to some extent. This study laid a foundation for the application of metabolomics in early diagnosis of pulmonary hypertension and provided experimental evidence for the application of sGC003 compound. In this study, the program of animal testing had been approved by Committee on the management of experimental animal in the Beijing Rixin Technology Co. Ltd.

This study aimed to address the protective role of Guilingji (GLJ) against hydrocortisone-induced Kidney-Yang deficiency syndrome in rats with metabolites in serum, and explore its regulative approaches. KidneyYang deficiency syndrome rat model was constructed by high-dose injection of hydrocortisone. Rats were randomly divided into 6 groups:control group, model group, positive (Jinkui Shenqi Wan) group and low, medium, or highdose group of GLJ for continuous administration over 30 days. The efficacy of GLJ was evaluated with traditional pharmacodynamic indicators (body weight, behavioral indicators, and biochemical parameters) after the model was replicated successfully. Animal experimentation was approved according to the Committee on the Ethics of Animal Experiments of Shanxi University. Serum metabolic profiles obtained by UHPLC-Q Exactive Orbitrap-MS were used to explore metabolic regulation mechanism of GLJ. The results showed that GLJ could significantly improve Kidney-Yang deficiency syndrome. Pathway analysis showed that leucine-isoleucine metabolism, ether ester metabolism, and bile acid metabolism were the main pathways, with the main mechanism of action involving energy balance, intestinal homeostasis and immune function.

UDP-rhamnose is a rhamnose donor in a reaction catalyzed by UDP-rhamnose synthase (RHM), and plays an important role in the biosynthesis of rhamnoside compounds. The current literature suggests that there are only a few genes can encode the corresponding enzymes to participate in UDP-rhamnose biosynthesis in plants. In this study, two RHM genes (FmRHM1 & 2) were first cloned by using the transcriptomic data of Fallopia multiflora (Thunb) Harald and the multidimensional analysis, including bioinformatics, functional identification in vitro and tissue-specific expression analysis. The results showed that the open reading frame (ORF) of FmRHM1 & 2 genes both were 2 013 bp, encode proteins consisting of 670 amino acids with a calculated molecular mass of 75.6 kDa, and the theoretical isoelectric points of 6.20 and 7.19, respectively. Bioinformatic analysis also indicated that FmRHM1 & 2 contained 2 special sequences of GxxGxxG/A and YxxxK. The phylogenetic analysis showed that the FmRHM gene has a high homology with RHM of other species. The results of enzyme activity in vitro revealed that both recombinant FmRHM1 and FmRHM2 have catalytic activities for converting UDP-glucose into UDP-rhamnose. Measurements of tissue-specific expressions showed that the expression levels of FmRHM1 and FmRHM2 were lower in roots. On the contrary, the 2 genes showed significantly high expression in the stems and leaves. In conclusion, we have cloned and characterized the RHM gene function for the first time in F. multiflora. Here we have provided the preliminary data suggesting the need for further research on UDP-rhamnose biosynthesis by microorganisms.

Natural products with diverse structures and significant biological activities were important source of lead compounds, and have played a key role in the innovative drug development. Recently, China has been in the prior position in discovering of structurally diverse active natural products from natural medicines. In 2018, a series of natural products with novel structures and significant biological activities have been isolated and studied by scholars from China, and 73 molecules with novel carbon frameworks have been selected as "Hot of The Press" by Nat Prod Rep Journal. In this review, the original, structures and biological activities of 123 compounds of natural products research field in 2018 were briefly described, which was aimed to exhibit the highlights of natural products research from China in past year.

Microspheres based on polylactic acid-glycolic acid (PLGA) copolymer have unique advantages in pulmonary controlled drug delivery. However, the clearance mechanism dominated by lung macrophage phagocytosis greatly limits the long-term retention of drugs in the deep lung. In order to avoid the scavenging effect of lung macrophages, the PLGA microspheres coated by polyethylene glycol-distearoyl-glycero-phosphoethanolamine (PEG-DSPE) was designed in this study, and the effect of chain length of PEG-DSPE and its ratio on the macrophage uptake was investigated. With coumarin 6 as a fluorescent probe, the coumarin 6-loaded PLGA microspheres was prepared by premix membrane emulsification/solvent evaporation. The particle size was controlled to 3-5 μm and the encapsulation efficiency was over 90%. After incubation in the cell culture fluid for 48 h, the in vitro leakage of fluorescein from the microspheres was less than 1.5%, eliminating the interference of free fluorescein on the cellular uptake. Murine macrophages RAW264.7 cell line was selected for the in vitro cell study. The preparations showed little toxicity to cells in the cytotoxicity study. Results of the macrophage uptake study showed that PEG₅₀₀₀-DSPE and PEG₁₀₀₀₀-DSPE coated groups with both high and low proportions (PEG-DSPE/PLGA 1:1, 0.25:1) could significantly reduce the phagocytosis of macrophages to microspheres compared with the uncoated PLGA group. For PEG₂₀₀₀-DSPE coated microspheres, the effect of escaping macrophage phagocytosis could be achieved by increasing the ratio of polyethylene glycol (PEG) on the surface of particles. Overall, the chain length of PEG-DSPE and its ratio are the key factors affecting the macrophage uptake. In pulmonary controlled drug delivery, high molecular weight of PEG-DSPE (PEG₅₀₀₀-DSPE and PEG₁₀₀₀₀-DSPE) and the high ratio (PEG-DSPE/PLGA 1:1) of PEG₂₀₀₀-DSPE can be selected to escape the phagocytosis of alveolar macrophages and prolong the drug retention in the lungs.

To establish a quality evaluation method for Astragali Radix using polysaccharide as quality control index, we established the Astragalus polysaccharide and monosaccharide sugar spectra, and combined with immunological activity test. High performance liquid chromatography (HPLC) was used to establish the specific chromatograms of Astragalus polysaccharides and monosaccharides. The data were analyzed by multivariate statistical analysis and cluster analysis using SIMCA software and SPSS software to distinguish Astragalus membranaceus var. mongholicus from different habitats or planting methods. The activity was evaluated by testing mouse peritoneal macrophage phagocytosis using neutral red. The results showed that the content of polysaccharides and the ability of enhancing phagocytic activity of macrophages from imitation wild Astragali Radix in Shanxi Hunyuan was higher than cultured Astragali Radix. The polysaccharides of Astragali Radix from Shanxi Hunyuan, Shanxi Wuzhai and Gansu Longxi have similar molecular weight distribution, but the peak area of each part has a significant difference in the percentage of the total peak area. The part of the polysaccharide of Shanxi Astragalus membranaceus with a molecular weight of about 10 kDa is higher than that of Gansu. Principal component analysis (PCA) shows that Astragali Radix from Shanxi and Gansu can be separated. All three are composed of five monosaccharides such as rhamnose, glucose, galactose, arabinose and galacturonic acid. However, the Astragalus polysaccharides (APS) in the three regions have different ratios of monosaccharide substances. The PCA display can distinguish three different Astragalus membranaceus var. mongholicus. This study used a combination of fingerprint of carbohydrates and the effects of APS on cellular immune function to provide a basis for quality evaluation and quality control of different habitats or planting methods.

Alzheimer's disease (AD) is a neurodegenerative disease that seriously threatens the life of the elderly and there is no effective therapy to treat or delay the onset of this disease. Due to the multifactorial etiology of this disease, the multi-target-directed ligand (MTDL) approach is an innovative and promising method in search for new drugs against AD. In order to find potential multi-target anti-AD drugs through reposition of current drugs, the database of global drugs on market were mined by an anti-AD multi-target prediction platform established in our laboratory. As a result, inositol nicotinate, cyproheptadine, curcumin, rosiglitazone, demecarium, oxybenzone, agomelatine, codeine, imipramine, dyclonine, melatonin, perospirone, and bufexamac were predicted to act on at least one anti-AD drug target yet act against AD through various mechanisms. The compound-target network was built using the Cytoscape. The prediction was validated by molecular docking between agomelatine and its multiple targets, including ADORA2A, ACHE, BACE1, PTGS2, MAOB, SIGMAR1 and ESR1. Agomelatine was shown to be able to act on all the targets above. In conclusion, the potential drugs for anti-AD therapy in the database for global drugs on market was partially uncovered using machine learning, network pharmacology, and molecular docking methods. This study provides important information for drug reposition in anti-AD therapy.

In 2018, FDA approved 59 kinds of new drugs in all, breaking the record of 53 set in 1993. There were 34 types of small molecule drugs, which accounted for 64% of the whole new drugs. Of these 34 new small molecule drugs, 9 first-in-class ones marked a milestone for the subsequent drug discovery and development. These include Glasdegib, the world's first small molecule inhibitor targeting Smo through Hedgehog signaling pathway; Ivosidenib, the first small molecule inhibitor targeting mutant IDH1; Tecovirimat, the first small molecule drug for anti-variola virus therapy through targeting p37; Baloxavir marboxil, the first anti-flu drug targeting cap-dependent endonuclease; Elagolix sodium, the first small molecule inhibitor in treating endometriosis by targeting GnRH-R, etc. The research and development of first-in-class drugs is always full of obstacles and challenges. However, once they were successfully recognized as the "heavy bomb" drugs, they would become huge benefits. This article chose the representative first-in-class small molecule drugs that were approved in 2018 as examples to analyze their development processes in an attempt to provide guidance for the research and development of more first-in-class drugs.